This clinical trial is focused on studying the treatment of a condition called severe uveitis in people with Behçet’s disease. Uveitis is an inflammation inside the eye that can lead to vision problems, and Behçet’s disease is a rare disorder that causes blood vessel inflammation throughout the body. The study will compare two treatments: tocilizumab and adalimumab. Tocilizumab is a medication given as an injection under the skin, and it works by blocking a protein in the body that can cause inflammation. Adalimumab is also an injection that helps reduce inflammation by targeting a specific protein involved in the body’s immune response.
The purpose of this study is to assess the benefits of tocilizumab compared to adalimumab in treating sight-threatening uveitis in Behçet’s disease. Participants in the study will receive either tocilizumab or adalimumab and will be monitored over a period of time to see how well the treatments work in reducing eye inflammation and improving vision. The study will also look at how these treatments affect the need for other medications, like corticosteroids, which are often used to control inflammation.
Throughout the study, participants will have regular check-ups to monitor their eye health and overall well-being. The study aims to provide valuable information on the effectiveness and safety of these treatments for people with severe uveitis due to Behçet’s disease. This research could help improve treatment options and outcomes for patients with this challenging condition.
France 
